Forget the 10,000-step myth; your ability to cover a specific distance in just ten minutes is the ultimate indicator of your ...
CHICAGO, IL—The pool of patients who could potentially benefit from a glucagon-like peptide 1 (GLP-1) receptor agonist has expanded, thanks to new data showing that people with diabetes and ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the ...